Elevation Oncology’s Claudin 18.2 Targeting ADC Earns FDA Fast Track Designation for Gastric Cancer

Elevation Oncology, Inc. (NASDAQ: ELEV), a biopharmaceutical company based in the U.S., has announced that it has received Fast Track designation (FTD) from the U.S. Food and Drug Administration (FDA) for its investigational therapy EO-3021 (SYSA1801). This antibody-drug conjugate (ADC) targets Claudin 18.2 and is being developed for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer that express Claudin 18.2. The therapy is intended for patients who have seen their cancer progress on or after receiving prior treatments.

EO-3021 (SYSA1801) originated with CSPC Pharmaceutical Group Ltd (HKG: 1093), a Chinese pharmaceutical company. Elevation obtained the rights to develop and commercialize the drug outside of Greater China in a licensing agreement valued at USD 1.195 billion, which was established in July 2022.- Flcube.com

Fineline Info & Tech